Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers-Reference-Cited by-同舟云学术

Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers

Published:2015-08 Issue:8 Volume:21 Page:551-558
ISSN:1341-321X
Container-title:Journal of Infection and Chemotherapy
language:en
Short-container-title:Journal of Infection and Chemotherapy

Author:

Tominaga Nobumitsu,Edeki Timi,Li James,Learoyd Maria,Bouw M. René,Das Shampa

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Infectious Diseases,Pharmacology (medical),Microbiology (medical)

Reference35 articles.

1. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region;Hsueh;J Infect,2011

2. In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART);Liu;Int J Antimicrob Agents,2012

3. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009–2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART);Lu;Int J Antimicrob Agents,2012

4. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004–2009;Rosenthal;Am J Infect Control,2012

5. Distribution of Extended-Spectrum β-Lactamases, AmpC β-Lactamases, and Carbapenemases among Enterobacteriaceae Isolates Causing Intra-Abdominal Infections in the Asia-Pacific Region: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic parameters of CAZ–AVI in the normal lung and in models of pneumonia: lessons for treatment optimization in critical care;Journal of Chemotherapy;2024-01-30

2. Pharmacokinetics of YK‐1169 in healthy subjects and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation;British Journal of Clinical Pharmacology;2023-06-20

3. A therapeutic regimen of ceftazidime-avibactam for a critical patient receiving prolonged intermittent renal replacement therapy;Journal of Infection and Chemotherapy;2023-06

4. Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors;Antibiotics;2021-06-24

5. Optimizing pharmacokinetics/pharmacodynamics of β-lactam/β-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria;Journal of Antimicrobial Chemotherapy;2020-10-10